AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
WEIGHT-LOSS, SKIN RASH, AND COUGH FOLLOWING BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA
Authors: WITHERSPOON RP MCGLAVE P CAMPBELL JB ROLSTON KVI
Citation: Rp. Witherspoon et al., WEIGHT-LOSS, SKIN RASH, AND COUGH FOLLOWING BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA, Cancer practice, 6(4), 1998, pp. 202-205
CURRENT THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
Authors: MCGLAVE P
Citation: P. Mcglave, CURRENT THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA, Leukemia & lymphoma (Print), 30, 1998, pp. 20-21
BIOLOGY AND THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA - PREFACE
Authors: MCGLAVE P VERFAILLIE CM
Citation: P. Mcglave et Cm. Verfaillie, BIOLOGY AND THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA - PREFACE, Hematology/oncology clinics of North America, 12(1), 1998, pp. 11-12
UNRELATED DONOR TRANSPLANT THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA
Authors: MCGLAVE P
Citation: P. Mcglave, UNRELATED DONOR TRANSPLANT THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA, Hematology/oncology clinics of North America, 12(1), 1998, pp. 93
CHRONIC LEUKEMIAS - RESPONSE
Authors: MCGLAVE P
Citation: P. Mcglave, CHRONIC LEUKEMIAS - RESPONSE, Experimental hematology, 26(7), 1998, pp. 549-549
G-CSF MOBILIZED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL DONATIONS BY RELATIVES - SIDE-EFFECTS AND SAFETY ISSUES
Authors: EASTLUND T DRAGOVICH S STRONCEK D MCGLAVE P
Citation: T. Eastlund et al., G-CSF MOBILIZED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL DONATIONS BY RELATIVES - SIDE-EFFECTS AND SAFETY ISSUES, Transfusion, 38(10), 1998, pp. 2-2
ANALYSIS OF 390 MARROW TRANSPLANTS FOR THE TREATMENT OF CHRONIC MYELOID-LEUKEMIA FROM UNRELATED DONORS FACILITATED BY THE US NATIONAL-MARROW-DONOR-PROGRAM(R) (NMDP) - EFFECT OF HLA-DRB1 ALLELE DISPARITY ON CLINICAL OUTCOME
Authors: PETERSDORF EW KOLLMAN C HURLEY C DUPONT B BEGOVICH A HANSEN J HARTZMAN R NADEMANEE A MCGLAVE P
Citation: Ew. Petersdorf et al., ANALYSIS OF 390 MARROW TRANSPLANTS FOR THE TREATMENT OF CHRONIC MYELOID-LEUKEMIA FROM UNRELATED DONORS FACILITATED BY THE US NATIONAL-MARROW-DONOR-PROGRAM(R) (NMDP) - EFFECT OF HLA-DRB1 ALLELE DISPARITY ON CLINICAL OUTCOME, Human immunology, 55, 1997, pp. 30-30
G-CSF MOBILIZED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL DONATIONS BY RELATIVES - SIDE-EFFECTS AND SAFETY ISSUES
Authors: DRAGOVICH S EASTLUND T MCGLAVE P MCCULLOUGH J
Citation: S. Dragovich et al., G-CSF MOBILIZED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL DONATIONS BY RELATIVES - SIDE-EFFECTS AND SAFETY ISSUES, Transfusion, 37(9), 1997, pp. 313-313
LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 AFTER AUTOLOGOUS BMT SAFELY AUGMENTS NK ACTIVITY
Authors: MILLER JS TUCK J WEISDORF D MCGLAVE P BLAZAR B KATSANIS E VERFAILLE C LEBKOWKSI J RADFORD J BURNS L
Citation: Js. Miller et al., LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 AFTER AUTOLOGOUS BMT SAFELY AUGMENTS NK ACTIVITY, Experimental hematology, 24(9), 1996, pp. 349-349
CYCLOPHOSPHAMIDE GM-CSF PRIMING IN AUTOTRANSPLANT THERAPY FOR CML/
Authors: MCGLAVE P BHATIA R VERFAILLIE C
Citation: P. Mcglave et al., CYCLOPHOSPHAMIDE GM-CSF PRIMING IN AUTOTRANSPLANT THERAPY FOR CML/, Bone marrow transplantation, 17, 1996, pp. 65-66
RELAPSE AFTER NON-T-CELL-DEPLETED ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA - EARLY TRANSPLANTATION USE OF ANUNRELATED DONOR, AND CHRONIC GRAFT-VERSUS-HOST DISEASE ARE PROTECTIVE
Authors: ENRIGHT H DAVIES SM DEFOR T SHU X WEISDORF D MILLER W RAMSAY NKC ARTHUR D VERFAILLIE C MILLER J KERSEY J MCGLAVE P
Citation: H. Enright et al., RELAPSE AFTER NON-T-CELL-DEPLETED ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA - EARLY TRANSPLANTATION USE OF ANUNRELATED DONOR, AND CHRONIC GRAFT-VERSUS-HOST DISEASE ARE PROTECTIVE, Blood, 88(2), 1996, pp. 714-720
ANALYSIS OF 328 MARROW TRANSPLANTS FOR THE TREATMENT OF CHRONIC MYELOID-LEUKEMIA FROM UNRELATED DONORS FACILITATED BY THE US NATIONAL MARROW DONOR PROGRAM (NMDP) - EFFECT OF HLA-DRB1 ALLELE DISPARITY ON CLINICAL OUTCOME
Authors: PETERSDORF EW HURLEY C DUPONT B BEGOVITCH A HANSEN J HARTZMAN R KOLLMAN C NADEMANEE A MCGLAVE P
Citation: Ew. Petersdorf et al., ANALYSIS OF 328 MARROW TRANSPLANTS FOR THE TREATMENT OF CHRONIC MYELOID-LEUKEMIA FROM UNRELATED DONORS FACILITATED BY THE US NATIONAL MARROW DONOR PROGRAM (NMDP) - EFFECT OF HLA-DRB1 ALLELE DISPARITY ON CLINICAL OUTCOME, Blood, 88(10), 1996, pp. 1062-1062
G-CSF VS GM-CSF PRIMED BONE-MARROW STEM-CELLS (BMSC) OR PERIPHERAL-BLOOD STEM-CELLS (PBSC) FOR AUTOTRANSPLANTATION - A RANDOMIZED COMPARISON OF ENGRAFTMENT AND RELAPSE
Authors: WEISDORF D BURROUGHS J MILLER J MCGLAVE P WAGNER J RAMSAY N BURNS L VERFAILLIE C
Citation: D. Weisdorf et al., G-CSF VS GM-CSF PRIMED BONE-MARROW STEM-CELLS (BMSC) OR PERIPHERAL-BLOOD STEM-CELLS (PBSC) FOR AUTOTRANSPLANTATION - A RANDOMIZED COMPARISON OF ENGRAFTMENT AND RELAPSE, Blood, 88(10), 1996, pp. 1569-1569
THE FIRST 1000 UNRELATED DONOR TRANSPLANTS FOR CML - LESSONS FROM THENATIONAL MARROW DONOR PROGRAM (NMDP) EXPERIENCE
Authors: MCGLAVE P KOLLMAN C SHU XO ANASETTI C NADEMANEE A CHAMPLIN R ANTIN J KERNAN N KING R
Citation: P. Mcglave et al., THE FIRST 1000 UNRELATED DONOR TRANSPLANTS FOR CML - LESSONS FROM THENATIONAL MARROW DONOR PROGRAM (NMDP) EXPERIENCE, Blood, 88(10), 1996, pp. 1922-1922
SUBCUTANEOUS IL-2 AFTER AUTOLOGOUS BMT EXPANDS NK IN-VIVO BUT REQUIRES EX-VIVO HIGH-DOSE IL-2 FOR MAXIMAL ACTIVATION
Authors: MILLER JS TESSMERTUCK J PIERSON BA WEISDORF D MCGLAVE P BLAZAR B KATSANIS E VERFAILLE C BURNS L
Citation: Js. Miller et al., SUBCUTANEOUS IL-2 AFTER AUTOLOGOUS BMT EXPANDS NK IN-VIVO BUT REQUIRES EX-VIVO HIGH-DOSE IL-2 FOR MAXIMAL ACTIVATION, Blood, 88(10), 1996, pp. 2426-2426
LUPUS INHIBITORS FOLLOWING BONE-MARROW TRANSPLANT
Authors: GREENO EW HAAKE R MCGLAVE P WEISDORF D VERFAILLIE C
Citation: Ew. Greeno et al., LUPUS INHIBITORS FOLLOWING BONE-MARROW TRANSPLANT, Bone marrow transplantation, 15(2), 1995, pp. 287-291
INTERACTION OF PRIMITIVE HUMAN MYELOID AND LYMPHOID PROGENITORS WITH THE MARROW MICROENVIRONMENT
Authors: MCGLAVE P VERFAILLIE C MILLER J
Citation: P. Mcglave et al., INTERACTION OF PRIMITIVE HUMAN MYELOID AND LYMPHOID PROGENITORS WITH THE MARROW MICROENVIRONMENT, Blood cells, 20(1), 1994, pp. 121-128
LARGE-SCALE EX-VIVO EXPANSION AND ACTIVATION OF HUMAN NATURAL-KILLER-CELLS FOR AUTOLOGOUS THERAPY
Authors: MILLER JS KLINGSPORN S LUND J PERRY EH VERFAILLIE C MCGLAVE P
Citation: Js. Miller et al., LARGE-SCALE EX-VIVO EXPANSION AND ACTIVATION OF HUMAN NATURAL-KILLER-CELLS FOR AUTOLOGOUS THERAPY, Bone marrow transplantation, 14(4), 1994, pp. 555-562
AUTOGRAFTING FOR CHRONIC MYELOCYTIC-LEUKEMIA
Authors: MCGLAVE P
Citation: P. Mcglave, AUTOGRAFTING FOR CHRONIC MYELOCYTIC-LEUKEMIA, Bone marrow transplantation, 14, 1994, pp. 49-50
ENDOGENOUS IL-2 PRODUCTION BY NATURAL-KILLER-CELLS (NK) MAINTAINS CYTOTOXIC AND PROLIFERATIVE CAPACITY FOLLOWING RETROVIRAL-MEDIATED GENE-TRANSFER
Authors: MILLER JS BLAZAR BR MCGLAVE P ORCHARD PJ
Citation: Js. Miller et al., ENDOGENOUS IL-2 PRODUCTION BY NATURAL-KILLER-CELLS (NK) MAINTAINS CYTOTOXIC AND PROLIFERATIVE CAPACITY FOLLOWING RETROVIRAL-MEDIATED GENE-TRANSFER, Blood, 84(10), 1994, pp. 10000289-10000289
HIGHER INCIDENCE OF RELAPSE IN RELATED COMPARED WITH UNRELATED DONOR RECIPIENTS FOLLOWING ALLOGENEIC MARROW TRANSPLANT FOR CML - ANALYSIS IN 290 PATIENTS
Authors: ENRIGHT H DAVIES S SHU X MILLER W WEISDORF D VERFAILLIE C MILLER J ARTHUR D DUSENBURY K RAMSAY N KERSEY J VERCELLOTTI G MCGLAVE P
Citation: H. Enright et al., HIGHER INCIDENCE OF RELAPSE IN RELATED COMPARED WITH UNRELATED DONOR RECIPIENTS FOLLOWING ALLOGENEIC MARROW TRANSPLANT FOR CML - ANALYSIS IN 290 PATIENTS, Blood, 84(10), 1994, pp. 10000336-10000336
NATURAL-KILLER-CELLS CAN BE DERIVED FROM CD34-CORD BLOOD( UMBILICAL)
Authors: HAN CS MCGLAVE P MILLER JS
Citation: Cs. Han et al., NATURAL-KILLER-CELLS CAN BE DERIVED FROM CD34-CORD BLOOD( UMBILICAL), Blood, 84(10), 1994, pp. 10000419-10000419
AUTOLOGOUS MARROW TRANSPLANT THERAPY FOR CML USING MARROW TREATED EX-VIVO WITH HUMAN RECOMBINANT INTERFERON-GAMMA
Authors: MCGLAVE P MILLER J MILLER W PERRY E FAUTSCH S RAMSAY NKC VERFAILLIE CM WEISDORF D
Citation: P. Mcglave et al., AUTOLOGOUS MARROW TRANSPLANT THERAPY FOR CML USING MARROW TREATED EX-VIVO WITH HUMAN RECOMBINANT INTERFERON-GAMMA, Blood, 84(10), 1994, pp. 10000537-10000537
DIFFERENTIATION OF NATURAL-KILLER (NK) CELLS FROM HUMAN PRIMITIVE MARROW PROGENITORS IN A STROMA-BASED LONG-TERM CULTURE SYSTEM - IDENTIFICATION OF A CD34(+)7(+) NK PROGENITOR
Authors: MILLER JS ALLEY KA MCGLAVE P
Citation: Js. Miller et al., DIFFERENTIATION OF NATURAL-KILLER (NK) CELLS FROM HUMAN PRIMITIVE MARROW PROGENITORS IN A STROMA-BASED LONG-TERM CULTURE SYSTEM - IDENTIFICATION OF A CD34(+)7(+) NK PROGENITOR, Blood, 83(9), 1994, pp. 2594-2601
RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG)
Authors: ROWE JM CIOBANU N ASCENSAO J STADTMAUER EA WEINER RS SCHENKEIN DP MCGLAVE P LAZARUS HM
Citation: Jm. Rowe et al., RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG), Annals of internal medicine, 120(2), 1994, pp. 143-158
Risultati: 1-25 | 26-36